Similar articles

• Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.

  Pande AC, Greiner M, Adams JB, Lydiard RB, Pierce MW. Pande AC, et al. Biol Psychiatry. 1999 Sep 15;46(6):860-2. doi: 10.1016/s0006-3223(99)00090-6. Biol Psychiatry. 1999. PMID: 10494457 Clinical Trial.
• Peripheral axotomy influences the in vivo release of cholecystokinin in the spinal cord dorsal horn-possible involvement of cholecystokinin-B receptors.

  Gustafsson H, de Araújo Lucas G, Schött E, Stiller CO, Alster P, Wiesenfeld-Hallin Z, Brodin E. Gustafsson H, et al. Brain Res. 1998 Apr 20;790(1-2):141-50. doi: 10.1016/s0006-8993(98)00060-2. Brain Res. 1998. PMID: 9593865
• Anxiolytic effects of CCK-B antagonists.

  Costall B, Domeney AM, Hughes J, Kelly ME, Naylor RJ, Woodruff GN. Costall B, et al. Neuropeptides. 1991 Jul;19 Suppl:65-73. doi: 10.1016/0143-4179(91)90084-v. Neuropeptides. 1991. PMID: 1679211
• [Cholecystokinin receptor antagonists].

  Ohtsuka T, Yokose K. Ohtsuka T, et al. Tanpakushitsu Kakusan Koso. 1993 Aug;38(11):1853-62. Tanpakushitsu Kakusan Koso. 1993. PMID: 8210429 Review. Japanese. No abstract available.
• Functional role of brain CCK receptors.

  Woodruff GN, Hill DR, Boden P, Pinnock R, Singh L, Hughes J. Woodruff GN, et al. Neuropeptides. 1991 Jul;19 Suppl:45-56. doi: 10.1016/0143-4179(91)90082-t. Neuropeptides. 1991. PMID: 1881532 Review. No abstract available.